The University of Pittsburgh and proposes to conduct a Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer. The overall goals of the Pittsburgh Head and Neck SPORE are to improve the detection, and treatment of head and neck cancer. The SPORE program will consist of four translational research projects in head and neck cancer, two research cores, a developmental research program and a career development program. The University of Pittsburgh Head and Neck SPORE will use an interdisciplinary approach to meet its objectives by carrying out projects with co-investigators in basic, applied and clinical science. It is also organ-specific in that its approach and all projects will test hypotheses about head and neck cancer biology, susceptibility, detection, or treatment. The long-term goal of the Head and Neck SPORE is to conduct clinical studies based on research results from the translational research projects, that will serve as the basis for improving the outcome of patients diagnosed with head and neck cancer. The four main projects include: (1) Cyclin D1 and XPD polymorphisms as potential risk factors of SCCHN; (2) Targeting Activated Stat3 in Head and Neck Cancer; (3) Wild Type p53-based Adjuvant Immunotherapy for SCCHN; and (4) Targeting EGFR and GPCR Signaling in SCCHN. The two research cores will interact closely to assist the main research projects, developmental research projects and the career development investigators in carrying out translational head and neck cancer research. The research cores include: (1) Histology/Tissue Banking and (2) Biostatistics and Informatics. The Head and Neck SPORE investigators will work together to synergistically achieve the goals of the program and will also interact with investigators from SPOREs at other institutions to improve the outcome of patients with cancer of the head and neck.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097190-04
Application #
7267746
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (M1))
Program Officer
Ujhazy, Peter
Project Start
2004-07-01
Project End
2009-06-30
Budget Start
2007-08-10
Budget End
2008-06-30
Support Year
4
Fiscal Year
2007
Total Cost
$2,184,766
Indirect Cost
Name
University of Pittsburgh
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Njatcha, Christian; Farooqui, Mariya; Kornberg, Adam et al. (2018) STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer. Mol Cancer Ther 17:1917-1926
Johnston, Paul A; Sen, Malabika; Hua, Yun et al. (2018) High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Methods Mol Biol 1683:229-244
Palliyaguru, Dushani L; Yuan, Jian-Min; Kensler, Thomas W et al. (2018) Isothiocyanates: Translating the Power of Plants to People. Mol Nutr Food Res 62:e1700965
Gleber-Netto, Frederico O; Zhao, Mei; Trivedi, Sanchit et al. (2018) Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124:84-94
Santuray, Rodell T; Johnson, Daniel E; Grandis, Jennifer R (2018) New Therapies in Head and Neck Cancer. Trends Cancer 4:385-396
Liu, Zhuqing; McMichael, Elizabeth L; Shayan, Gulidanna et al. (2018) Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res 24:4529-4538
Lu, Shanhong; Concha-Benavente, Fernando; Shayan, Gulidanna et al. (2018) STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. Oral Oncol 78:186-193
Nikiforova, Marina N; Mercurio, Stephanie; Wald, Abigail I et al. (2018) Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer 124:1682-1690
Zhong, Qian; Liu, Zhi-Hua; Lin, Zhi-Rui et al. (2018) The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res 24:659-673
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054

Showing the most recent 10 out of 310 publications